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Abstract
Background: This study was designed to evaluate the psychiatrists' level of recognition of somatic
symptoms associated to a major depressive episode (MDE) (DSM-IV-TR criteria) and the impact
of those somatic symptoms on the treatment effectiveness.
Methods: This non-interventional study was conducted in 25 medical offices in Puerto Rico from
February to December 2003. It had 2 visits separated by 8 weeks. The level of recognition was
determined by: the correlation between the physician clinical evaluation and their patients' self-
evaluations through different validated instruments using kappa statistics. Chi-square test was used
to evaluate the impact of somatic symptoms on treatment antidepressants' effectiveness.
Results: All the 145 recruited patients reported the presence of at least one somatic symptom
associated with their current MDE. In the two visits covered by the study, a fair agreement between
the psychiatrists' and the patients' reports was noted for headache, abdominal pain and upper limb
pains (0.4003 ≤ κ ≥ 0.6594). For other painful symptoms and painless somatic symptoms, the Kappa
values obtained were non-significant. Slight but significant reductions in depression and painful
symptoms severity were observed after 8 weeks of treatment. A proportional relationship
between the pain and depression severity was observed (p < 0.0001).
Conclusion: The study results show that somatic symptoms: are very common in depressed
Puerto Rican patients; are significant under-reported by psychiatrists; and have a significant impact
on the antidepressant effectiveness.
Background
Although recent epidemiological studies have not demon-
strated any differences in the prevalence rate of major
depressive disorders in the Latino and Caucasian popula-
tions living in the United States [1], the Hispanic Health
and Nutrition Examination Survey (Hispanic HANES),
when compared to the Epidemiological Catchment Area
(ECA) Study, showed that Puerto Ricans living in the
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symptomatology, followed by Caucasians, Mexican-
Americans and Cuban-Americans [2-4]. Unfortunately,
little is known about the prevalence of major depression
in adults living in the island of Puerto Rico. Data suggest
lower lifetime prevalence rates (4.3% – 4.6%) [5,6] in
comparison to the US mainland (16.2%) [1].
Traditionally, diagnostic classification systems have
focused on the emotional symptoms of a major depres-
sive episode (MDE), such as depressed mood, markedly
diminished interest or pleasure in almost all activities,
and feelings of worthlessness, among others [7]. Never-
theless, the importance of somatic symptoms, also known
as physical symptoms, in depressed patients has been well
established. It is estimated that 69% to 92% of the
patients have somatic symptoms [8-11]. Studies con-
ducted in primary care settings [12-18] have shown signif-
icant association between major depression and painless
somatic symptoms such as: vague and exaggerated multi-
ple somatic complaints (usually more than three), fatigue,
weakness, non-specific and painless musculoskeletal
problems, sensations of heaviness or lightness in at least
one part of the body, gastrointestinal dysfunction, short-
ness of breath, palpitations, dizziness, double vision,
changes in sleep patterns and appetite, and polyuria. Sim-
ilarly, significant association between major depression
and painful somatic symptoms such as joint pains, lum-
bar pain and headache has also been reported [12-18]. In
some cases, these somatic symptoms constitute the princi-
pal reason for consultation rather than the emotional
symptoms [19]. Moreover, some studies have shown that
the presence of somatic symptoms contributes greatly to
the recurrence of another new depressive episode several
years later [15,20-24]. In addition, this association appar-
ently does not depend on social or economic factors such
as gender, income level, education or age, but it is rather
inherent to the condition just as emotional symptoms are
[25-27].
Somatic symptoms have been described as part of a cul-
tural language of affective disorders that, if misinterpreted
by the clinician, can lead to unnecessary diagnostic proce-
dures or to inadequate treatment [28]. Studies with
depressed patients treated in a primary care setting show
that somatic and anxiety symptoms are often overlooked
in the diagnosis of depression despite such symptoms
contributing significantly to detecting the disease, accord-
ing to a recent logistic regression analysis [29]. In a study
with primary care treated outpatients (n = 1, 456), 70% of
whom were Latinos, the prevalence of somatization was
22%. Of the sub-sample with somatization, 35% had a
Major Depressive Disorder (MDD) compared to only
13.7% for those without somatization (p < 0.0001) [30].
Studies comparing Latino populations with MDD resid-
ing in Colombia, Peru and Puerto Rico versus non-Latino
populations with MDD in the United States, show gener-
ally higher indices of somatization despite similar rates of
depressive symptoms [25,31,32].
However, very little is known about the role of somatic
symptoms in populations of depressed patients treated by
psychiatrists. It is possible that this group of physicians
fails to recognize, value, or else underestimates the pres-
ence of these type of symptoms as an integral part of
major depression and, therefore, does not monitor their
evolution during the course of treatment. Some unan-
swered questions are: prevalence of somatic symptoms in
depressed patients evaluated by psychiatrists, level of rec-
ognition of such symptoms by psychiatrists, clinical rele-
vance of somatic symptoms in a psychiatric practice,
impact of somatic symptoms on recovery and remission
in depressed patients treated with different antidepres-
sants, differences between available antidepressant medi-
cations in the improvement of painful or painless somatic
symptoms.
In an effort to clarify some of these questions, we con-
ducted an observational study in Puerto Rico. Our
research method allowed for the collection of data from a
representative group of psychiatrists on their level of rec-
ognition of painful or painless somatic symptoms, com-
pared to the reports of their patients with a MDE without
interfering with their usual clinical practice.
Methods
Selection of patients
The recruiting phase took place between February and
December 2003 in 25 private outpatient psychiatry prac-
tices geographically distributed throughout Puerto Rico.
Male and female subjects over 21 years of age diagnosed
with MDE according to the Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition, Text Revision
(DSM-IV-TR) were eligible for the study. Patients were
excluded from the study if they had participated in clinical
studies thirty (30) days prior to the first study visit. They
were also excluded if they were hospitalized or met the
diagnostic criteria for: refractory depression, defined as
poor response to two or more appropriate antidepressant
treatments for at least 12 to 16 weeks, according to the
guidelines published by Souery et al. [33]; bipolar disor-
ders; psychotic disorders; dementia; secondary depres-
sion; or painful or painless somatic symptoms of known
etiology.
Study design
Before beginning the study, the protocol was reviewed
and approved by an institutional review board (IRB).
Before being subjected to any study procedure, the study
subjects signed an IRB approved informed consent formPage 2 of 13
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involved in the study.
Since this study was non-interventional, it did not contain
requirements or recommendations on antidepressant or
other treatment. The participating psychiatrists were free
to choose the type and course of treatment for each of
their patients to the best of their own clinical judgement
and in accordance to their usual practice. There were no
restrictions concerning the use of other therapies concom-
itantly with the antidepressant medication. Because the
investigation sites were the psychiatrists' own private
medical offices, research tools that interfered minimally
with the usual clinical practice were utilized to collect the
study data.
Primary and secondary measures
The presence, severity, and number of somatic symptoms
were recorded during two study visits separated by an 8
week interval, by means of the trained psychiatrists own
reports and a case report form with a table to list: all the
somatic symptoms asked to or reported by the patients
during the last 4 weeks, and the level of severity of each
one of them (1 = mild; 2 = moderate; 3 = marked; 4 =
severe). The patients, on the other hand, used a self-eval-
uation scale: the Somatic Symptom Inventory (SSI) [34].
The SSI is a 26-item questionnaire. In this inventory, the
patients' degree of discomfort for each symptom is rated
from 1 to 5 (1 = absent; 3 = moderate; 5 = a great deal). All
the investigators received a structured training before the
first patient visit. This training included a review of the
protocol, the case report forms, and the SSI scale. With
respect to the SSI, the psychiatrists were instructed to use
the scale as a general reference during the patient inter-
view and somatic symptom recording but not to follow
the scale's items or language literally because this could
affect the patient's spontaneous response to the self-
administered SSI at the end of the visit.
We categorized total SSI scores as minimal (= ≤ 52) and
moderate to high (= ≥ 52) according to the patients'
degree of somatic symptom discomfort. This post-hoc cut-
off point was arbitrarily determined based on the high
number (mean of 14) of reports by patients of somatic
symptoms causing at least some degree of discomfort.
Internal analysis supported this cut-off point to statisti-
cally differentiate between two groups of patients in terms
of depression severity and other variables discussed
below. We also conducted subscale analyses for both
painless (SSI items 1, 4–8, 10–13, 15–18, 20–26) and
painful (SSI items 2,3,9,14,19) somatic symptoms (Table
4). Because the SSI that we used only included 5 painful
somatic symptoms, limiting the options to detect any dif-
ference between the patients' and physicians' reports, we
decided to ask the patients with painful symptoms to
specify the location of their symptoms with the help of
human silhouettes and to rate the impact of the treat-
ments received on the magnitude of the pain using a Vis-
ual Analogue Scale (VAS).
The effects on the emotional and somatic symptoms of
antidepressant therapy, as selected by the psychiatrists,
were evaluated after the 8-week interval between the two
study visits. The Clinical Global Impression – Severity
(CGI-S) scale was used by the psychiatrists to evaluate any
changes in the severity of the MDE. Also, characteristic
major depressive episode emotional symptoms such as
depressed mood, guilt-related thoughts, feelings of worth-
lessness, anhedonia, psychomotor agitation or retarda-
tion, loss of concentration, anxiety, psychotic symptoms,
and suicide behavior or thoughts, were each analyzed
individually according to their clinically rated severity (1
= absent; 3 = moderate; 5 = severe). Patients evaluated also
the impact of antidepressant therapy in their MDE using
the Patient Global Impression – Improvement (PGI-I)
and a VAS for assessment of depression. Additional infor-
mation on the employment status, drug abuse or depend-
ency, concomitant therapies used to manage somatic
symptoms, and the efficacy of these therapies was also
collected.
Statistical methods
The study was designed with a power of 90% to detect
average differences in the level of recognition of at least
one somatic (physical) symptom greater or equal to 23%
by both groups analyzed, psychiatrists and patients,
according to the estimate obtained using the least squares
method, and based on previous data from studies on the
recognition of symptoms in primary care patients.
Correlation analyses used to determine the level of agree-
ment between the psychiatrists' evaluations and patient
self-evaluations were conducted using Kappa statistics.
Unanswered questions were not considered in the analy-
sis. Symptoms were classified using a sensitivity analysis,
considering the patients' report as point of comparison:
>0.75, high degree of agreement beyond chance; 0.40 to
0.75, fair agreement beyond chance and <0.40, low degree
of agreement.
The comparison of the number of symptoms reported by
the psychiatrists versus the patients was performed using
the statistical t test for independent samples. Secondary
analyses were conducted to evaluate any significant statis-
tical differences in clinical and demographic variables
between genders, age groups, employment status, type of
antidepressant medications, and the severity of the
depression. The chi-square test for variable categories was
used for this analysis.Page 3 of 13
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relationships between emotional and physical symptoms
reported by patients and clinicians, the level of recogni-
tion of emotional symptoms by psychiatrists as compared
to their patients' reports, and associations between differ-
ent symptoms and response levels to the different antide-
pressants. The level of significance was set at P = 0.05. In
order to describe the demographics of the study popula-
tion, a univariate analysis was conducted by calculating




A total of 145 patients were evaluated in the initial visit.
Table 1 presents the demographic values of the study pop-
ulation. Of the 145 patients that entered the study, 129
completed the procedures for visit 1 and 42 of them with-
drew from the study before visit 2. The most common
causes for withdrawing were: consent withdrawal
(13.2%), visit 2 outside the stipulated protocol window
(9.3%), researcher's decision (2.3%), and patients' change
in provider (1.6%). None of the patients withdrew from
the study because of adverse events or reasons related to
the medications prescribed by their physicians. This
report includes all the patients who completed at least the
initial visit. For the analysis comparing results at visit 2
versus visit 1 we used the data of the 87 completers.
For almost half the patients in the study, the clinicians
prescribed concomitant medications in addition to the
antidepressants they had selected. The concomitant med-
ications most frequently reported were anxiolytics (37.9%
of the patients), antipsychotics (10.6%), tricyclic antide-
pressants (13.6%) and analgesics (9.1%). At baseline,
alcohol consumption rates were reported for 28 of the
144 patients (19.4%). None of the patients admitted any
consumption of controlled substances.
Clinical findings
As mentioned in the Methodology section, patient
responses were used as points of reference for different
comparisons. Somatic symptom SSI patient self-reports
were correlated to psychiatrists' somatic symptom reports,
which the physician recorded during the patient interview
by using the SSI as a general reference. All the patients
included in the analysis reported at least one somatic
symptom in the SSI. A low agreement between the psychi-
atrist report and his patients for somatic painless symp-
toms was observed in both visits. The Kappa values
obtained for each painless somatic symptom were less
than 0.1159 (low degree of agreement) with variable sen-
sitivity ranged from 1.27% for walk balance difficulty to
18.81% for muscle twitches. In other words, the probabil-
ity of psychiatrists reporting the presence of any somatic
painless symptom in their patients with a MDE, which
reported having this symptom, was less than 19% in this
sample. In other way, a variable percentage of false nega-
tive were also reported, ranged from 81% for muscle
twitches to 100% for lump in throat, meaning that near all
painless somatic symptoms were erroneously interpreted
by the psychiatrist as present in some cases, but they were
not reported by the patient (Table 2). The total average
number of painless symptoms reported by the psychia-
trists was only an eighth of the number reported by the
patients (2 vs. 16; p < 0.001). The number of painless
somatic symptoms reported by the patient from baseline
to endpoint visit was similar, showing consistency and no
improvement despite treatment of their MDE (p = 0.999).
No significant differences in the number of painless
somatic symptoms were observed when data was adjusted
for gender or age.
With regards to the painful somatic symptoms, contrary
to the painless ones, a fair agreement between the psychi-
atrist report and his patients was observed for upper limbs
joint pains, abdominal pain, back pain and headache
(0.4008 < κ >0.5788). Variable sensitivity ranged from
46.7% for shoulder pain to 77.2% for headache, this
being one of the symptoms with higher sensitivity. Other
painful symptoms, including pain in the lower limbs and
joints, showed a low degree of agreement with lower sen-
sitivity values. With regards to the percentage of false neg-
atives, these ranged from 22% for headache to 66% for
lower limb pain (Table 3). The number of painful symp-
toms reported by psychiatrists was half that reported by
their patients (1.5 vs. 3; p < 0.001). The number of painful
Table 1: Demographic variables of the study population (initial 
visit)
Variable N Value or % 
(SD)
Average Age (st. dev.) 145 44.5 (11.77)
Gender: Female 113 77.93%
Race and Ethnicity
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showing little change despite treatment of their MDE (p =
0.1453). No significant differences in the number of pain-
ful symptoms were observed when data was adjusted for
gender or age.
In spite of minimal changes in the number of somatic
symptoms between both study visits, we observed some
changes in the patients' degree of discomfort according to
the SSI scores. Some symptoms exhibited a little but
significant score reduction, although not enough to be
considered absent after the 8 weeks of treatment (Table
4).
The data obtained from the SSI in the initial visit allowed
us to observe certain characteristics common to our pop-
ulation sample. For example, one hundred percent of the
patients reported some type of somatic symptom associ-
ated with their major depressive episode. This percentage
did not vary after an average of 8 weeks of treatment with
different antidepressants selected by the treating clini-
cians. Age, female gender, and unemployment were varia-
bles significantly associated with the presence of somatic
symptoms (p < 0.05). The severity of the depression
according to the patient self-evaluation was greater in
those patients with moderate to high degree of discomfort
with their somatic symptoms (p < 0.001) (Table 5).
With respect to emotional symptoms, in the first visit only
17.5% of the patients were classified with a mild clinical
depression by the psychiatrists, and the average score of
the total CGI-S was 4.3. This suggests a moderate to high
level of severity of depression for the study sample in gen-
eral. Likewise, all individual emotional symptoms were
Table 2: Relationship between the treating psychiatrists and the patients reports of painless somatic symptoms
SSI Symptom Kappa Coefficient* N Sensitivity (%)† False negative (%)†
Nausea/Vomiting 0.1159 131 12.70 87
Constipation 0.0594 128 6.85 93
Dizziness 0.0521 133 10.75 89
Muscle twitches 0.0512 133 18.81 81
Breathlessness 0.0418 133 6.58 93
Fatigue 0.0261 133 9.48 90
Weakness 0.0225 133 4.85 95
Palpitations 0.0201 131 6.33 93
Lump in throat 0.0151 133 NA 100
Walk balance difficulty 0.0105 135 1.27 98
Head/nose fullness 0.0085 133 1.92 98
Body Numbness 0.0042 134 3.19 96
Other Symptoms 0.0000 132 NA NA
*Kappa Coefficient: <0.75 = high degree of agreement beyond chance; 0.40 to 0.75 = fair agreement beyond chance; <0.40 = low degree of 
agreement. †For major explanation regarding sensitivity and false negative items please refer to the principal text.
NA = Non applicable.
Table 3: Relationship between the treating psychiatrists and the patients reports of painful somatic symptoms
Type of Pain Kappa Coefficient* N Sensitivity (%)† False negative (%) †
Hand Pain 0.5788 125 64.52 55
Abdominal Pain 0.5710 125 57.14 42
Shoulder Pain 0.5303 125 46.67 53
Back Pain 0.4180 125 62.71 37
Headache 0.4008 125 77.22 22
Knee pain 0.4034 125 39.13 60
Lower limb pain 0.3826 125 33.33 66
Foot Pain 0.3736 125 44.44 55
Other Pains 0.00 – 0.32 125 6.8 – 28.5 71 – 95
*Kappa Coefficient: <0.75 = high degree of agreement beyond chance; 0.40 to 0.75 = fair agreement beyond chance; <0.40 = low degree of 
agreement. †For major explanation regarding sensitivity and false negative items please refer to the principal text.Page 5 of 13
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35% of the patients reported moderate to severe feelings
of guilt and/or hopelessness according to his psychiatrist.
Thirty-eight percent reported moderate to severe anhedo-
nia, 34.3% psychomotor changes, 42.4% loss of concen-
tration, 31.9% significant levels of anxiety, 36.1%
psychotic symptoms, and 31.9% suicidal thoughts.
At the end of 8 weeks of treatment with various antide-
pressants, there was a significant reduction in the basal
score of the total CGI-S and in each of the depressive
symptoms analyzed (p < 0.0001). Nevertheless, the aver-
age score in visit 2 was 3.2 and 38.1% of patients main-
tained moderate to high levels of severity. Only 13% of
the patients achieved a score of ≤ 2 on the CGI-S (border-
line depression or normal). Patients also reported feeling
better with antidepressant treatment during visit 2 as
reflected by a reduction in the total average PGI-I score
(3.22 to 2.73; p < 0.0019) and the VAS score (from 0.63
to 0.49 p < 0.0001). No significant statistical differences
in visit 2 VAS scores were noted between patients who
were already on antidepressant therapy in visit 1 (87.5%)
and those who were not, but this finding could be due to
the sample size.
In general, although depressive symptoms decreased sig-
nificantly in visit 2 compared to visit 1, a similar trend was
not detected for somatic symptoms. No improvement was
noted in the painless somatic symptoms as reflected by
visits 1 and 2 SSI subscale scores (51.6 and 52.5 respec-
tively; p = NS). Slight reduction in the degree of discom-
fort due to the following somatic symptoms was noted:
dizziness, fatigue, muscle twitches, poor physical health,
body numbness, weakness and "feeling bad". However,
there were no appreciable changes in gastrointestinal, sen-
sory and cardiopulmonary symptoms during the 8 weeks
Table 4: Somatic symptoms (SSI) scores: degree of discomfort analysis (V2 vs V1) (n = 88)*
SSI Symptom SSI Score (Visit 1) SSI Score (Visit 2) ‡ p-Value
1. Nausea and vomiting 1.8 1.6 NS
2. Muscles soreness 2.3 2.1 <0.05
3. Pains or cramps in your abdomen 2.0 1.8 NS
4. Feeling faint or dizzy 2.4 2.0 <0.05
5. Trouble with your vision 2.2 2.1 NS
6. Muscles twitching or jumping 3.1 2.6 <0.05
7. Feeling fatigued, weak, or tired all over 3.4 2.9 <0.05
8. A fullness in your head or nose 2.6 2.3 NS
9. Pain in your lower back 3.2 2.6 <0.05
10. Constipation 2.4 2.2 NS
11. Trouble catching your breath 2.1 1.9 NS
12. Hot or cold spells 2.4 2.3 NS
13. A ringing or buzzing in your ears 2.0 1.8 NS
14. Pains in your heart or chest 2.3 1.9 <0.05
15. Difficulty keeping your balance while walking 2.2 1.9 NS
16. Indigestion, upset stomach, or acid stomach 2.7 2.4 NS
17. The feeling that you are not in as good physical health as most of your friends 3.4 2.9 <0.05
18. Numbness, tingling, or burning in parts o your body 2.7 2.2 <0.05
19. Headaches 3.3 2.6 <0.05
20. A lump in your throat 2.2 2.0 NS
21. Feeling weak in parts of your body 2.9 2.4 <0.05
22. Not feeling well most of the time in the past few years 3.4 2.9 <0.05
23. Heavy feelings in your arms or legs 2.9 2.6 NS
24. Your heart pounding, turning over or missing a beat 2.4 2.0 NS
25. Your hands and feet not feeling warm enough 2.2 1.8 NS
26. The sense that your hearing is not as good as it used to be 2.4 2.1 NS
Painless subscale† 51.6 52.5 NS
Painful subscale 13.0 11.0 <0.05
Total SSI 63.4 56.8 <0.05
*SSI – Somatic Symptom Inventory (degree of discomfort: 1 = absent; 2 = a little bit; 3 = moderate; 4 = quite a bit; 5 = a great deal); ‡ 8 weeks after 
Visit 1; † Somatic painless subscale correspond to the SSI items: 1, 4–8, 10–13, 15–18, 20–26.
NS = Non significantPage 6 of 13
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noted in visits 1 and 2 SSI subscale scores for painful
symptoms (13 and 11, respectively; p < 0.05) and total SSI
scores (63.4 and 56.8 respectively; p < 0.05).
The relation between the patients' degree of discomfort
with their somatic symptoms and the severity of their
emotional symptoms was also analyzed. This study did
not reveal any relation between the patients' level of
response to antidepressant treatment and their degree of
discomfort due to somatic symptoms (painless or pain-
ful) in visit 1. Patients with minimal as well as those with
moderate to high degree of discomfort due to somatic
symptoms demonstrated significant reductions on the
CGI-S at the end of 8 weeks of treatment (Figure 1). Slight
but significant reductions in depression and painful
symptoms severity according with the Pain relief Visual
Analogue Scale and the PGI-I – both of which were rated
by the patients – were observed after 8 weeks of treatment.
A proportional relationship between the pain and depres-
sion severity was observed (p < 0.0001) (Figure 2).
Discussion
Somatization is common to all cultures and social groups
studied. However, there are differences in the styles of
expression and attribution of symptoms according to the
beliefs and health practices of each culture [35-38]. Soma-
tization has been more frequently associated with Latino
populations than with other ethnic groups [31]. It has
been mentioned that societies that promote individual-
ism with clear limits in interpersonal relations seem to
value the direct expression of unpleasant feelings. On the
other hand, collective societies with more flexible levels of
relationships tend to place greater value on the indirect
expression of feelings (idiom of distress hypothesis) [39].
The Psychological Problems in the General Health Care
study (PPGHC) of the World Health Organization
(WHO) was conducted in 14 cities from the same number
of countries on four continents. It showed that adult
patients treated in primary outpatient care centers were
characterized by a high prevalence of reports of somatic
symptoms in the two participating Latino cities (Rio de
Janeiro in Brazil and Santiago in Chile), compared to the
total sample (32% and 36.5% vs. 19.7%), according to
the SSI scale. These results did not depend on the level of
development, education, or gender of the cities evaluated
[40]. The WHO study did not demonstrate culture to have
a determining role in the manifestation of somatic symp-
toms except for the two Latin American cities evaluated.
Cultural differences can even be observed within different
Latino populations in the prevalence of somatic symp-
toms or chronic pain. A comparative study of Mexican-
Americans, natives living in Puerto Rico, and Caucasian-
Americans used an analysis of 5 clusters of symptoms and
demonstrated that the Puerto Ricans presented the high-
est levels of somatization [25,41]. In other publications,
the same authors concluded that since the high rates of
somatization in Puerto Ricans were not accompanied by
higher rates of prevalence of depressive disorders com-
Table 5: Sample characteristics at initial visit according to the total SSI score*
Variable Minimum degree of 
discomfort (n = 34)¶
Moderate/High degree of 
discomfort (n = 87)¶
p-Value
Average SSI Score (st.dev.) 41.0 (7.7) 76.06 (16.65) <0.001
Average Age (st.dev.) 40.69 (13.23) 45.5 (10.00) 0.0193
Gender:
Female (77.9%) 29.25 70.75 0.034
Employment Status:
Employed (58.5%) § 41.30 58.70 0.013
Antidepressants:
SSRIs (61%)† T 34.88 65.12 0.553
Other antidepressants 29.03 70.97
(26.5%) †
Total VAS Score ‡ 49.8 70.8 <0.001
*SSI – Somatic Symptom Inventory; §Includes housewives and students; T Includes fluoxetine, setraline, paroxetine, citalopram; † Includes 
venlafaxine and bupropion; ‡ Self-evaluation analogue visual scale of the depression scored by the patients; ¶Minimum degree of discomfort due to 
somatic symptoms (SSI ≤ 52 – 26 items); Moderate/high degree of discomfort due to somatic symptoms (SSI > 52 – 26 items).Page 7 of 13
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attributing somatic symptoms as "psychogenic" and not
considering them manifestations of a MDE [42,43].
Another study of depressed patients living in the United
States reflected prevalence rates of chronic abdominal
pain that differed significantly between the three Latino
groups evaluated: 4.6% in Mexican-Americans; 5.8% in
Cuban-Americans; and 8.3% in Puerto Ricans. Logistic
regression analyses showed a close relation between
depression and chronic abdominal pain, female gender,
and single marital status [44].
In our study, a direct relationship between moderate to
high degree of discomfort due to somatic symptoms and
age, female gender and unemployment was also observed
(Table 5). In this study of Puerto Rican patients with a
MDE, 100% of patients reported somatic symptoms using
the SSI scale. Although this percentage is very high, previ-
ous depression trials in primary care settings have also
shown that 69% to 92% of MDE patients experience
somatic symptoms [8-11]. Somatization has been
reported to be particularly more prevalent in Puerto Rican
depressed patients than in other Hispanic populations.
However, we cannot exclude the possibility that the use of
an inventory such as SSI led to a higher number of somatic
symptom reports than would have been spontaneously
reported by patients. We could have avoided this poten-
tial bias by using a validated scale to collect information
on somatic symptoms as a primary research tool.
However, this would have precluded us from achieving
the primary objective of our study.
Communication between patients and their physicians is
influenced by various cultural factors such as the patient's
perception of her emotional and physical symptoms, her
report of these symptoms to the physician, and the physi-
cian's interpretation of the symptoms. These steps
described by Leff [45] in the communication of unpleas-
ant emotions could affect the final evaluation of the phy-
sician with respect to the clinical status of the patient.
Since 1960, significant differences have been shown
between patient self-evaluations of their depressive symp-
tomatology and the evaluations conducted by their physi-
cians. Carrol et al. [46] suggest that these differences are
due to discrepancies between the instruments used by the
patients and clinicians. They proved that the use of instru-
Analysis of the SSI total score related to the mean CGI-S scoreFigure 1
Analysis of the SSI total score related to the mean CGI-S score. The patients were divided into two groups according 
to their degree of discomfort with their somatic symptoms: minimum (≤ 52) (n = 29) and moderate/high (>52) (n = 50). CGI-S 
is measured from 1 to 7, where "1" corresponds to the absence of depressive symptoms and "7" to the greatest possible sever-
ity of depressive symptoms. Abbreviations: SSI – Somatic Symptom Inventory; CGI-S – Clinical Global Impression of Severity. 
*p < .001Page 8 of 13
(page number not for citation purposes)
BMC Psychiatry 2005, 5:28 http://www.biomedcentral.com/1471-244X/5/28ments with similar structure and matching items allow
higher correlation coefficients. Corruble et al. [47], using
structured instruments with similar items, demonstrated
in their study with 64 hospitalized depressed patients that
there was significant agreement between the patients and
the psychiatrists' report of the severity of the depression.
Nevertheless, depressed patients with high levels of soma-
tization and anxiety exhibited a tendency to overestimate
their symptomatology compared to what was reported by
their physicians. To date, few studies have explored the
level of agreement in the recognition of somatic symp-
toms between patients and physicians. A study with pri-
mary care physicians showed that these clinicians and
their patients can be more comfortable with somatic
symptoms than with emotional symptoms, which leads
to an under-reporting of depression in those patients with
associated physical symptoms [48]. Contrary to this, a
review focused on the recognition of somatoform disor-
ders by psychiatrists indicated that these specialists are
more concerned with severe mental disorders than with
the recognition of somatic symptoms. Psychiatrists
attempt to "normalize" the physical symptoms expressed
by their patients and tend to refer them to other specialists
[49].
In this study, despite similar SSI mean scores for painful
and painless symptoms (2.6 vs. 2.5, respectively) (Table
4), when compared to painful symptoms of the torso,
upper limbs and head, painful symptoms of the lower
limbs and painless somatic symptoms showed a lack of
correlation between the psychiatrists' and the patients'
reports. The marked difference between psychiatrists' and
patients' somatic symptoms reports may be explained by
the different methods used to document somatic symp-
toms and degree of discomfort caused by them, or may be
due to a tendency by psychiatrists to dismiss certain type
of pain or painless somatic symptoms in their usual clini-
cal practice. This study was purposefully designed to avoid
any intervention and allow for a naturalistic observation
of usual clinical psychiatric care in Puerto Rico. The use of
Relationship between pain severity and depression improvement (patient report)Figure 2
Relationship between pain severity and depression improvement (patient report). Regression analysis shows an 
inversely proportionate relationship between the severity of the pain reported by the patients and the level of improvement 
from the major depressive episode according to the patients' global impression (PGI-I) (n = 87). Abbreviations: VAS – Visual 
Analogue Scale; PGI-I – Patient Global Impression of Improvement.Page 9 of 13
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not have been representative of the usual clinical practice
and would not have allowed us to document the degree of
recognition of somatic symptoms in MDE patients in this
clinical setting.
Additionally, we observed that those somatic symptoms
with lower sensitivity percentages usually have higher
false negative percentages than those with fair agreement
levels (Tables 2 &3). This suggest that psychiatrists may
not only omit several somatic symptoms in their patients
with MDE but may also detect and document other symp-
toms unreported by their patients. This observation may
be a result of the study design, which in itself could have
increased the psychiatrists' motivation to report somatic
symptoms and may not represent necessarily their usual
clinical practice.
Failure to detect somatic symptoms in depressed patients
may have significant implications in the cost of treatment.
Reid et al. [50] compared the health-care utilization pat-
terns of patients with medically unexplained symptoms
with those of other frequently referred patients. "Somatis-
ing patients" had at least two medical consultation visits
for unexplained physical symptoms, a greater number of
referrals for secondary care and were more likely to
undergo additional clinical work-up and tests. In other tri-
als, rates of health resources utilization for MDD patients
with somatic symptoms were nine times higher than for
the general population and three times higher than for all
depressed patients [51,52]. Moreover, individuals with
MDD consistently exhibit the highest rates of loss of
productive time (LPT) when they concomitantly present
symptoms like pain, weakness, fatigue, gastrointestinal
discomfort or sensory changes [53]. Given the duration
and size of the sample, this study did not show differences
in certain variables related to the use of health resources
such as consumption of analgesics or other medications.
However, it did reflect a higher rate of unemployment in
patients with moderate to high severe somatic symptoms.
Additionally, failure to detect somatic symptoms in
depressed patients has significant impact in the response
to treatment. The presence of physical symptoms in MDD
patients has been associated with a poor level of response
to antidepressant treatment [54]. Appropriate treatment
to control non-emotional symptoms is essential in order
to achieve proper compliance with therapy [55], to
decrease the risk of recurrences [56], to maximize earlier
initiation of the antidepressant action [57], and to
increase the opportunities for complete remission of the
depressive episode [58]. In this study, although there was
a significant reduction in the average CGI-S depression
score, only 13% of the patients reached a level of remis-
sion defined post-hoc as CGI ≤ 2.
Several studies with Selective Serotonin Reuptake Inhibi-
tors (SSRIs) have demonstrated that depressed patients
with somatic symptoms exhibit lower rates of response
than those without somatic symptoms [54,59,60]. Addi-
tionally, somatic symptoms respond less to SSRIs than
non-somatic symptoms [61]. According to several authors
[7,62,63], antidepressants that act dually on the
noradrenaline and serotonin pathways could be better
candidates for treating both depression and concomitant
somatic symptoms. In this study, 61% of the patients were
treated with a SSRI and 13% with low doses of venlafaxine
(average 56 mg/day). Clinicians did not report differ-
ences, according to the CGI-S, in the level of antidepres-
sant response between patients with minimal and those
with moderate to high degree of discomfort with their
somatic symptoms. Nevertheless, it was possible to deter-
mine that those patients who reported less relief of pain-
ful symptoms exhibited lower levels of reduction in the
PGI-I for depression. In other words, although psychia-
trists were not able to observe significant differences in the
level of response to treatment, patients who had less relief
of painful symptoms reported a lower response to antide-
pressant treatment (Figure 2). This difference in the
reporting of the response to treatment could be due to the
emphasis placed by psychiatrists on detecting and con-
trolling emotional symptoms rather than somatic symp-
toms. It also suggests that inappropriate identification of
somatic symptoms may lead to an erroneous perception
of appropriate antidepressant treatment response vis-à-vis
the experience of the patient.
Our study has a number of strengths. Through a confirm-
atory analysis, we explicitly tested the level of recognition
of somatic symptoms in patients with a MDE by their psy-
chiatrists. This analysis was conducted for all the somatic
symptoms as a group and separately according the pres-
ence of pain or not. We studied a random sample of the
population, and we used valid and reliable measures.
One potential limitation in our study is the use of the SSI,
which is a valid tool to detect the presence and degree of
discomfort due to somatic symptoms. However, the SSI is
probably more predictive in the case of anxiety disorders
than in depression and has a reduced sensitivity in the
detection of symptom changes due to treatment [64].
Another possible limitation is our use of a spontaneous
report measure for somatic symptoms by psychiatrists. A
structured psychiatric interview may have yielded differ-
ent results. However, spontaneous reports were the only
way not to bias the researchers' responses. In addition,
patient reports constituted the gold standard for the anal-
ysis of data despite the absence of scales or figures to guide
the patient in his response, potentially yielding an incom-
plete report of symptoms.Page 10 of 13
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iting factor. Although the study attempted to reproduce as
faithfully as possible the usual psychiatry practice in
Puerto Rico with appropriate representation throughout
the Island, exclusion and inclusion criteria limited access
to hospitalized patients with refractory depression, sui-
cidal behavior and associated medical conditions. These
are well-known factors that increase the presence of phys-
ical symptoms in patients with major depression [14,17].
Only Latino patients living in Puerto Rico were evaluated.
Given the importance of cultural factors in measuring the
objectives set forth in this study, it will be difficult to gen-
eralize the data to other Latino populations and even less
so to other ethnic groups or cultures.
Another potential limitation is the size of the sample. On
the one hand, it made possible the detection of significant
differences between psychiatrists and their patients with a
MDE in the reporting of physical symptoms, but it did not
allow confirmation of the impact of antidepressants in the
control of physical symptoms. A dichotomous classifica-
tion of the clinical response of emotional and physical
symptoms rather than a continuous measurement of their
evolution was used because of the limited sample size.
Finally, the short period of time between the two visits (8
weeks), the absence of intermediate visits and the lack of
treatment compliance measurements may limit conclu-
sions on the response to antidepressant therapy.
Conclusion
In summary, these results confirm reports from previous
clinical trials about the high rate of somatic symptoms in
Puerto Rican patients with a MDE [25,41,44]. Collec-
tively, our data reflect a significant difference in the report
of several somatic symptoms – pain in lower limbs and
joints and painless symptoms – by the psychiatrists and
their patients. Age, female gender, and unemployment are
variables significantly associated with the presence of
somatic symptoms. The severity of the depression accord-
ing to the patient self-evaluation is greater in patients with
moderate to severe discomfort due to somatic symptoms.
Although depressive symptoms in general reflected a sig-
nificant reduction in visit 2 compared to visit 1, 38.1% of
patients still had moderate to high severity depression and
only 13% had CGI-S scores of ≤ 2 (borderline or normal
depression). Slight but significant reductions in depres-
sion and painful symptoms severity were observed
according to the patient evaluations after 8 weeks of treat-
ment. However, a proportional inverse relationship
between the pain relief and depression severity was
observed. This finding suggests that physical symptoms
must be appropriately recognized by psychiatrists because
they can interfere with the physicians' assessment of the
magnitude of response to antidepressant treatment.
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